Healthcare Equipment and Supplies
Company Overview of TYRX, Inc.
TYRX, Inc. manufactures and markets absorbable and non-absorbable antibacterial envelopes/implantable devices for cardiovascular, cosmetic surgical, and other pharmaceutical applications. The company offers its products to stabilize cardiac implantable devices; and reduce surgical site infection rates and treatment costs for high-risk patients. It serves customers worldwide. TYRX, Inc. was formerly known as TYRX Pharma, Inc. The company was founded in 1998 and is based in Monmouth Junction, New Jersey. As of December 30, 2013, TYRX, Inc. operates as a subsidiary of Medtronic plc.
1 Deer Park Drive
Monmouth Junction, NJ 08852
Founded in 1998
Key Executives for TYRX, Inc.
Vice President of Advanced Products
Vice President of Product Development
Compensation as of Fiscal Year 2015.
TYRX, Inc. Key Developments
TYRX, Inc. Announces First Implantation of AIGISRx R Fully Bioresorbable Antibacterial Envelope
Aug 7 13
TYRX, Inc. announced that the first implantation of its new AIGISRx R Fully Resorbable Antibacterial Envelope has taken place at the Vanderbilt Heart and Vascular Institute in Nashville, TN by Dr. Christopher R. Ellis. The AIGISRx R Antibacterial Envelope received U.S Food and Drug Administration (FDA) clearance on May 20, 2013. The AIGISRx R device is a fully bioresorbable, antibacterial mesh envelope, intended to hold Cardiac Implantable Electronic Devices (CIEDs), such as pacemakers and implantable cardioverter defibrillators (ICDs) securely in place to provide a stable environment when implanted in the body. The AIGISRx R contains the antimicrobial agents rifampin and minocycline, which are released locally into the tissue to help reduce Surgical Site Infections (SSIs) associated with CIED implantation. Multiple studies have shown that patients at high risk for CIED infection who are implanted with the AIGISRx Antibacterial Envelope had 70% to 100% fewer device infections than similar patients who did who did not receive the AIGISRx. Vanderbilt Heart and Vascular Institute recently performed a matched cohort study to compare the incidence of CIED infection in patients receiving a CIED with or without an AIGISRx Antibacterial Envelope. After a minimum of 90days of follow-up, the incidence of CIED infection was significantly lower in the group that received the AIGISRx, compared to those that did not (0.4% vs. 3.0%, OR = 0.13 [0.02-0.95],p=0.04). There were 87% fewer CIED infections in patients who received the AIGISRx, compared to those who did not.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries